Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial

Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. • Merck & Co stock is showing upward bias. What’s ahead for MRK stock?The trial showed Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically significant and clinically meani ...